- Home
- ARMP vs WEA Comparison
ARMP vs WEA Comparison
Compare ARMP & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARMP | WEA |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 130.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARMP | WEA |
|---|---|---|
| Price | $6.42 | $11.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 54.2K | 46.1K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,054,000.00 | N/A |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $9.60 |
| 52 Week High | $16.34 | $11.29 |
Technical Indicators
Market Signals| Indicator | ARMP | WEA |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 41.96 |
| Support Level | $5.75 | $11.16 |
| Resistance Level | $6.37 | $11.23 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 33.19 | 0.00 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.